ArticleBMC pediatrics2026
The influence of early intravenous immunoglobulin administration on the prognosis of severe hemolytic disorders in neonates.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere hemolytic disorders in neonates can lead to anemia, jaundice, and potentially severe neurological impairment or death. Early intravenous immunoglobulin (IVIG) administration has gained attention for its potential to mitigate hemolysis and its complications. But the optimal timing of IVIG remains a topic of debate. Therefore, this study aims to investigate the influence of early IVIG administration on the prognosis of severe hemolytic disorders in neonates.
methodsA retrospective analysis of clinical data from 58 cases of neonatal severe hemolytic disease admitted to hospital (January 1, 2022-December 3, 2025) was conducted. The cases were divided into an early IVIG (n = 29) and control (n = 29) groups based on whether immunoglobulin was administered within 12 h of birth. Baseline characteristics, hemoglobin values, total bilirubin levels, cumulative phototherapy time, and incidence of complications were assessed.
resultsBaseline characteristics were well-matched between the two groups. Hemoglobin levels at 7 days after treatment in the early IVIG group was significantly decreased compared to control. The cumulative phototherapy duration in the early IVIG group was also significantly higher than control. Furthermore, the early IVIG group had a significantly higher incidence of severe jaundice. Correlation analysis showed significant associations between early IVIG administration and hemoglobin levels, cumulative phototherapy time, and the incidence of severe jaundice.
conclusionEarly IVIG administration in neonates with severe hemolytic disorders may be associated with a more rapid decline in hemoglobin levels, prolonged duration of phototherapy, and increased incidence of severe jaundice.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.